![Giuseppina Caligiuri](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Giuseppina Caligiuri first degree
Entity | Entity type | Industry | |
---|---|---|---|
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Giuseppina Caligiuri via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Advent Venture Partners LLP
![]() Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
IsoTis, Inc.
![]() IsoTis, Inc. Medical SpecialtiesHealth Technology IsoTis, Inc. designs, manufactures and sells bone graft substitutes and other devices. The company was founded on November 15, 2006 and is headquartered in Plainsboro, NJ. | Medical Specialties | Corporate Officer/Principal | |
Arthur D. Little, Inc.
![]() Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree | |
Organon International, Inc.
![]() Organon International, Inc. Pharmaceuticals: MajorHealth Technology Organon International, Inc. manufactures and markets pharmaceutical products. It develops therapeutics in the fields such as gynecology, fertility, osteoporosis, and anesthesia. The company was founded in 1923 and is located in Roseland, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Strathclyde | College/University | Undergraduate Degree | |
Agendia NV
![]() Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Director/Board Member | |
NEOVACS | Pharmaceuticals: Major | President | |
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
University of Utrecht | College/University | Graduate Degree | |
AM-Pharma Holding BV
![]() AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
University of Hagen | College/University | Undergraduate Degree | |
Tc Land Expression SA
![]() Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Miscellaneous Commercial Services | Founder | |
Orthocon, Inc.
![]() Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Medical Specialties | Director/Board Member | |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Bellevue Asset Management (Venture Capital)
![]() Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Investment Managers | Private Equity Investor | |
Manchester Business School | College/University | Masters Business Admin | |
Natural Dental Implants AG
![]() Natural Dental Implants AG Medical SpecialtiesHealth Technology Natural Dental Implants AG provides dental technology products and services. The firm specialized in the development of Replicate, a non-surgical tooth replacement system designed to alternative preserve alveolar bone and adjacent teeth. It offers an alternative solutions to traditional dental implants and three unit dental bridges, with focus on three-dimensional image and impression, natural healing, and temporary and permanent crown features. The company was founded by Ruedger Rubbert and Lea Ellermeier Nesbit in 2009 and is headquartered in Berlin, Germany. | Medical Specialties | Director/Board Member | |
The University of North Carolina at Charlotte | College/University | Graduate Degree | |
HeatMatrix Group BV
![]() HeatMatrix Group BV Building ProductsProducer Manufacturing HeatMatrix Group BV develops and manufactures plastic heat exchangers for waste heat recovery from industrial corrosive flue gas. The firm’s heat exchangers can be used in the petrochemicals and chemicals, bio-energy, food, agricultural, and paper industries. Its products include air pre-heater, hybrid exchanger, gas to liquid, and in situ cleaning system. The company was founded by Erik van den Berg in 2008 and is headquartered in Geldermalsen, the Netherlands. | Building Products | Founder | |
Amal Therapeutics SA
![]() Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Chief Operating Officer | |
Luxfold S.A.
![]() Luxfold S.A. BiotechnologyHealth Technology Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg. | Biotechnology | Founder | |
Memo Therapeutics AG
![]() Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Executive Officer | |
OSE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Chief Operating Officer | |
Step Pharma SAS
![]() Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman | |
Orphalan SA
![]() Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman | |
AdBio Partners SAS
![]() AdBio Partners SAS Investment ManagersFinance AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France. | Investment Managers | Founder | |
Swiss Healthcare Licensing Group | Director/Board Member | ||
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor | |
LAVA THERAPEUTICS N.V. | Biotechnology | Founder | |
Igyxos SA
![]() Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France. | Pharmaceuticals: Major | Director/Board Member | |
Alentis Therapeutics AG
![]() Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Alliance Manchester Business School | College/University | Masters Business Admin | |
Urania Therapeutics SAS
![]() Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Biotechnology | Chairman | |
The School of Pharmacy University of London | College/University | Doctorate Degree | |
Pheno Therapeutics Ltd.
![]() Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
Alderaan Biotechnology SAS
![]() Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Augustine Therapeutics NV
![]() Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member | |
Vico Therapeutics BV
![]() Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
DiogenX SAS
![]() DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Biotechnology | Director/Board Member | |
Pandeia Therapeutics Ltd. | Founder | ||
Lead Pharma Holding BV
![]() Lead Pharma Holding BV Pharmaceuticals: MajorHealth Technology Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Vaximm AG
![]() Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman |
Statistics
International
France | 12 |
Switzerland | 11 |
Netherlands | 9 |
United Kingdom | 8 |
United States | 6 |
Sectoral
Health Technology | 25 |
Consumer Services | 11 |
Finance | 5 |
Commercial Services | 5 |
Health Services | 3 |
Operational
Director/Board Member | 28 |
Chairman | 8 |
Founder | 7 |
Corporate Officer/Principal | 7 |
Chief Executive Officer | 7 |
Most connected contacts
Insiders | |
---|---|
Klaus Breiner | 16 |
Erik van den Berg | 13 |
Alain Huriez | 12 |
Fraser Murray | 8 |
Laurence de Schoulepnikoff | 5 |
Benoit Barteau | 3 |
- Stock Market
- Insiders
- Giuseppina Caligiuri
- Company connections